Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.562 EUR 1.83%
Market Cap: 144m EUR

Wall Street
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 4.995 EUR with a low forecast of 2.414 EUR and a high forecast of 6.51 EUR.

Lowest
Price Target
2.414 EUR
55% Upside
Average
Price Target
4.995 EUR
220% Upside
Highest
Price Target
6.51 EUR
317% Upside
Innate Pharma SA Competitors:
Price Targets
KRYS
Krystal Biotech Inc
9% Downside
300122
Chongqing Zhifei Biological Products Co Ltd
32% Upside
LCTX
Lineage Cell Therapeutics Inc
169% Upside
145020
Hugel Inc
55% Upside
6855
Ascentage Pharma Group International
89% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
10% Upside
CRVO
Diffusion Pharmaceuticals Inc
182% Upside
688363
Bloomage Biotechnology Corp Ltd
9% Upside

Revenue
Forecast

Revenue Estimate
Innate Pharma SA

For the last 13 years the compound annual growth rate for Innate Pharma SA's revenue is 4%. The projected CAGR for the next 4 years is 51%.

4%
Past Growth
51%
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
30%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IPH's stock price target?
Price Target
4.995 EUR

According to Wall Street analysts, the average 1-year price target for IPH is 4.995 EUR with a low forecast of 2.414 EUR and a high forecast of 6.51 EUR.

What is Innate Pharma SA's Revenue forecast?
Projected CAGR
51%

For the last 13 years the compound annual growth rate for Innate Pharma SA's revenue is 4%. The projected CAGR for the next 4 years is 51%.

Back to Top